ClearBridge Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

ClearBridge Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-197,518	Closed	-$14M	–	712
2025 Q1	$14M	Sell	197,518 -12,736	-6%	-$857K	0.01%	448
2024 Q4	$13.8M	Sell	210,254 -35,140	-14%	-$2.35M	0.01%	487
2024 Q3	$17.2M	Sell	245,394 -14,179	-5%	-$1.19M	0.01%	467
2024 Q2	$21.4M	Sell	259,573 -1,529	-0.6%	-$127K	0.02%	441
2024 Q1	$22.8M	Sell	261,102 -9,741	-4%	-$872K	0.02%	442
2023 Q4	$26.1M	Sell	270,843 -160,576	-37%	-$14.2M	0.02%	432
2023 Q3	$38.2M	Sell	431,419 -1,758	-0.4%	-$156K	0.04%	344
2023 Q2	$37.5M	Sell	433,177 -37,906	-8%	-$3.57M	0.03%	359
2023 Q1	$45.8M	Sell	471,083 -631,206	-57%	-$65.4M	0.04%	331
2022 Q4	$114M	Sell	1,102,289 -71,414	-6%	-$6.7M	0.11%	186
2022 Q3	$99.5M	Buy	1,173,703 +48,615	+4%	+$4.33M	0.1%	192
2022 Q2	$93.2M	Sell	1,125,088 -984,288	-47%	-$78.4M	0.09%	220
2022 Q1	$163M	Sell	2,109,376 -3,154,216	-60%	-$264M	0.12%	165
2021 Q4	$465M	Buy	5,263,592 +74,239	+1%	+$6.13M	0.32%	86
2021 Q3	$401M	Buy	5,189,353 +118,050	+2%	+$9.31M	0.29%	91
2021 Q2	$423M	Buy	5,071,303 +67,333	+1%	+$5.34M	0.29%	88
2021 Q1	$378M	Sell	5,003,970 -1,018,442	-17%	-$83.2M	0.28%	90
2020 Q4	$528M	Sell	6,022,412 -149,916	-2%	-$11.9M	0.41%	66
2020 Q3	$470M	Buy	6,172,328 +262,570	+4%	+$26.6M	0.4%	64
2020 Q2	$729M	Sell	5,909,758 -403,944	-6%	-$40.1M	0.66%	36
2020 Q1	$534M	Buy	6,313,702 +115,236	+2%	+$9.93M	0.58%	50
2019 Q4	$521M	Buy	6,198,466 +155,752	+3%	+$11.8M	0.43%	67
2019 Q3	$407M	Buy	6,042,714 +68,440	+1%	+$5.27M	0.36%	80
2019 Q2	$512M	Buy	5,974,274 +968,956	+19%	+$82.9M	0.44%	70
2019 Q1	$445M	Buy	5,005,318 +499,656	+11%	+$46.3M	0.39%	84
2018 Q4	$384M	Buy	4,505,662 +455,271	+11%	+$43.3M	0.39%	81
2018 Q3	$393M	Buy	4,050,391 +378,902	+10%	+$37.8M	0.34%	91
2018 Q2	$346M	Buy	3,671,489 +2,253,624	+159%	+$197M	0.28%	106
2018 Q1	$115M	Buy	1,417,865 +70,699	+5%	+$6.07M	0.11%	177
2017 Q4	$120M	Sell	1,347,166 -43,724	-3%	-$3.8M	0.11%	185
2017 Q3	$129M	Buy	1,390,890 +35,068	+3%	+$3.1M	0.12%	167
2017 Q2	$123M	Buy	1,355,822 +22,864	+2%	+$2.08M	0.12%	170
2017 Q1	$117M	Buy	1,332,958 +516,663	+63%	+$46M	0.12%	176
2016 Q4	$67.6M	Buy	816,295 +90,850	+13%	+$7.81M	0.07%	224
2016 Q3	$67.1M	Buy	725,445 +76,405	+12%	+$7.19M	0.08%	220
2016 Q2	$50.5M	Buy	649,040 +13,233	+2%	+$1.12M	0.06%	264
2016 Q1	$52.4M	Buy	635,807 +66,546	+12%	+$5.41M	0.06%	254
2015 Q4	$59.6M	Sell	569,261 -59,607	-9%	-$6.22M	0.07%	242
2015 Q3	$66.2M	Sell	628,868 -20,363	-3%	-$2.72M	0.08%	229
2015 Q2	$88.8M	Buy	649,231 +60,790	+10%	+$7.53M	0.09%	201
2015 Q1	$73.3M	Sell	588,441 -110,949	-16%	-$11.8M	0.08%	234
2014 Q4	$63.2M	Sell	699,390 -62,435	-8%	-$5.19M	0.07%	257
2014 Q3	$55M	Sell	761,825 -4,259	-0.6%	-$280K	0.06%	279
2014 Q2	$47.7M	Sell	766,084 -4,323	-0.6%	-$261K	0.05%	298
2014 Q1	$52.5M	Sell	770,407 -35,749	-4%	-$2.63M	0.06%	269
2013 Q4	$56.7M	Buy	806,156 +97,758	+14%	+$6.64M	0.07%	259
2013 Q3	$51.1M	Buy	708,398 +260,052	+58%	+$17.3M	0.07%	260
2013 Q2	$25M	Buy	+448,346	New	+$27.9M	0.04%	351

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments's BMRN Position: Q2 2025 in Review

ClearBridge Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 197,518 shares — an estimated $14M sold.

ClearBridge Investments first reported a position in BMRN in Q2 2013 and held it in 48 quarters. The position peaked at $729M in Q2 2020. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

ClearBridge Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
ClearBridge Investments sold 197,518 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $14M.
ClearBridge Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 48 quarters.
ClearBridge Investments's BioMarin Pharmaceuticals position peaked at $729M in Q2 2020.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on ClearBridge Investments's 13F filing for Q2 2025, filed 12 Aug 2025.